NEW YORK, Feb. 14, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on NEOS, PCRX, PSDV, and TTPH which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com draws investors' attention to the Generic Drugs market, which can be segmented
Grand Prairie, Texas headquartered Neos Therapeutics Inc.'s stock finished Tuesday's session 0.26% higher at $9.50 with a total trading volume of 223,517 shares. The stock has gained 79.25% in the previous twelve months. The Company's shares are trading above their 200-day moving average by 9.63%. Moreover, shares of Neos Therapeutics, which engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder ausing its drug delivery technologies, have a Relative Strength Index (RSI) of 38.20. Get the full research report on NEOS for free by clicking below at: www.wallstequities.com/registration/?symbol=NEOS
Shares in Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc. declined 1.24%, ending yesterday's session at $35.90 with a total trading volume of 1.11 million shares, which was higher than their three months average volume of 854.40 thousand shares. The Company's shares are trading below their 50-day moving average by 13.90%. Moreover, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 37.32.
On January 19th, 2018, research firm Seaport Global Securities initiated a 'Buy' rating on the Company's stock, with a target price of $50 per share. Today's complimentary research report on PCRX is accessible at: www.wallstequities.com/registration/?symbol=PCRX
On Tuesday, Watertown, Massachusetts-based pSivida Corp.'s stock saw a rise of 1.92%, to close the day at $1.06. A total volume of 104,853 shares was traded. The stock is trading below its 50-day moving average by 6.19%. Additionally, shares of pSivida, which develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the US and the UK, have an RSI of 43.88. Register now for your free research document on PSDV at: www.wallstequities.com/registration/?symbol=PSDV
Shares in Watertown, Massachusetts headquartered Tetraphase Pharmaceuticals Inc. ended the day 0.55% lower at $5.43. A total volume of 758,565 shares was traded, which was above their three months average volume of 477.00 thousand shares. The stock has gained 7.95% over the last twelve months. The Company's shares are trading below their 50-day moving average by 10.75%. Furthermore, shares of Tetraphase Pharma, which develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections, have an RSI of 41.29.
On February 12th, 2018, research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the Company's stock, with a target price of $11 per share. Click on the link below and see our free report TTPH at: www.wallstequities.com/registration/?symbol=TTPH
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/whats-happening-with-these-generic-drugs-stocks----neos-therapeutics-pacira-pharma-psivida-and-tetraphase-pharma-300598565.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...View All